Cost-effectiveness analysis of dupilumab versus omalizumab, mepolizumab, and benralizumab added to the standard of care in adults with severe asthma in Colombia
Article in Expert Review of Pharmacoeconomics & Outcomes Research (February 2024)
The most recent citing publications are shown below. View all 42 publications that cite this research output on Dimensions.
Article in Expert Review of Pharmacoeconomics & Outcomes Research (February 2024)
Book chapter (January 2024)
Article in Journal of Clinical Medicine (September 2023)